


China Blood Products Industry Report, 2009



The blood products industry has a strong ability to withstand risks and immunity to global financial crisis since it is not greatly influenced by periodicity. Owing to large demand gap, strict supervision, high entry barrier and slower supply growth etc in blood products industry, the prices of China's blood products has soared up and corporate profitability also has increased significantly.

China's blood products industry has been in the transition of policy adjustment since 2003. The plasma collection registered approximately 3,100 tons in 2008 due to restrictions from raw materials and the changes in industry policy.

China's Plasma Collection, 2001-2010E




Source: ResearchInChina

The report makes an in-depth analysis of the status quo of China's blood product industry, points out the gap between Chinese blood products companies and overseas peers, predicts the development trends, and discusses the investment opportunities and risks. In addition, it also focuses on the research of current operation and development trend of China's seven key blood product companies, such as Hualan Biological Engineering Inc.

As a key company of blood products R&D and production in China, the revenue of Hualan Biological Engineering Inc achieved RMB475 million in 2008, up 35.32% year-on-year; and the total profit was RMB218 million, a 69.73% YoY rise. Moreover, the current and newly-built plasma collection stations primarily distribute in Guizhou, Guangxi and Chongqing. Up to 2008, it had owned 11 plasma collection stations, and three under construction. It has eased the short supply of plasma via building new plasma collection stations.

Hualan Biological Engineering has taken the lead in blood products field in China, in the meantime, it has accessed into vaccine sector actively. It was the first to obtain Influenza A strain on Jun 8, 2009, and it entered the clinical trials on July 22. The monthly output capacity of Influenza A vaccine can reach 7.5 million units, and it would carry the reserves of 4 million units before Sep 15. Besides, it had produced 13 million units of Influenza A vaccine before Oct 1. As is estimated, it can supply 35-40 million units of Influenza A vaccine by the end of 2009.

Prime Operating Revenue of Hualan Biological Engineering Inc, 2007-2011E



Source: ResearchInChina

Table of Contents

- **1 China's Blood Products Industry**
 - 1.1 Market
 - 1.1.1 Profile
 - 1.1.2 Industry Characteristics
 - 1.2 Competitive Patterns
 - 1.3 Existing Problems
 - 1.4 Development Trend
 -
- **2. China's Plasma Market**
 - 2.1 Plasma Collection Station
 - 2.2 Plasma Volume
 - 2.3 Plasma Price
 - 2.4 Difficulties in Industry Development
 - 2.5 Development Trend
- **3. Global Blood Products Industry**
 - 3.1 Development Courses
 - 3.2 Status Quo
 - 3.3 Comparison between China and International Blood Products Industry Development
 -
- **4. Key Blood Products**
 - 4.1 HSA
 - 4.2 IVIG
 - 4.3 HBIG
 - 4.4 Rabies Immunoglobulin
 - 4.5 Tetanus Immunoglobulin
 - 4.6 Coagulation Factor FVIII
- **5. Key Manufacturers in China**
 - 5.1 Overall Analysis
 - 5.2 Hualan Biological Engineering Ltd
 - 5.2.1 Profile
 - 5.2.2 Operation
 - 5.2.3 Development Trend
 - 5.3 Shanghai RAAS Blood Products Co., Ltd
 - 5.3.1 Profile
 - 5.3.2 Operation
 - 5.3.3 Development Trend
 - 5.4 CNBG Shanghai Institute of Biological Products
 - 5.4.1 Profile

- 5.4.2 Operation
- 5.5 Beijing Tiantan Biological Products Co., Ltd
 - 5.5.1 Profile
 - 5.5.2 Operation
 - 5.5.3 Development Trend
- 5.6 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd
 - 5.6.1 Profile
 - 5.6.2 Operation
- 5.7 Guiyang Qianfeng Biological Product Liability Co., Ltd.

- **6. Investment**
 - 6.1 Opportunities
 - 6.2 Risks
 - 6.3 Suggestions

Selected Charts

- Varieties, Applications and Manufacturers of China's Main Blood Products
- Management Modes of Plasma Collection Station before System-Reform
- Blood Product Industry Chain after System-Reform
- State's Laws & Regulations on Blood Products Industry
- Plasma Volume Trend of China's Blood Products, 2003-2011
- China's Plasma Collection Volume Trend, 2001-2010
- Comparison between China's and International Blood Product Market Structure, 2008
- China's HSA Output, 2005-2008
- China's HSA Prices, 2003-2010
- China's IVIG Output, 2003-2008
- China's IVIG Prices, 2003-2010
- Concentration Trend of Companies in the Future
- Plasma Collection Capability of Hualan Biological Engineering's Current and Would-be Plasma Collection Stations
- Revenue/Cost Structure of Hualan Biological Engineering, 2008
- Main Business Revenues of Hualan Biological Engineering, 2007-2011
- Profitability of Hualan Biological Engineering, 2008-2011
- The Number of Hualan Biological Engineering's Plasma Collection Stations, 2008
- China's Flu Vaccine Market Share, 2008
- Shanghai RAAS Revenue/Profit Ratio by Business, 2008
- Shanghai RAAS Revenue/Gross Profit Structure, 2008

- Shanghai RAAS Product Price Trend, 2005-2011
- Shanghai RAAS Projects Invested by Fund-Raising, 2008
- Output Capacity Comparison of Shanghai RAAS Fund-Raising Investment Projects before and after Completion, 2008
- The List of SIBP Products
- Revenue Trend of Beijing Tiantan Biological, 2008-2011
- Beijing Tiantan Biological Revenue Change before and after Acquisition of Chengdu Rongsheng
- Products List of Guiyang Qianfeng
- China's HSA Provisional Maximum Retail Price, 2008

How to Buy

Product details			How to Order
	USD	File	By email: report@researchinchina.com
Single user	1,200	PDF	By fax: 86-10-82600829
Enterprisewide	1,800	PDF	By online: www.researchinchina.com
Publication date: Oct. 2009			
For more information, call our office in Beijing, China:			
Tel: 86-10-82600828			
Website: www.researchinchina.com			